Recent revelations demonstrate that QCOR's drug Acthar was administered to patients who suffered hundreds of adverse events and several deaths.
Adverse events related to Acthar occur predominately in NS patients. A real safety study is needed as no large-scale study on NS patients has ever been performed.
QCOR's clinical trial results to-date leave much to be desired. Efficacy and safety are questionable. This may become a serious issue for MNK post-merger.
In a Seeking Alpha blog post last October we brought to light shady practices of the Chronic Disease Fund (CDF) as well as Questcor Pharmaceuticals' (NASDAQ:QCOR) all-too-cozy relationship with the charity. Since then, the CDF